Novartis' Bet Pays Off as Advanced Accelerator Applications Wins FDA Nod for Lutathera Post author:Sam Post published:January 25, 2018 Post category:BioPharma The drug is the first available FDA-approved Peptide Receptor Radionuclide Therapy. Source: BioSpace You Might Also Like Aquinox Announces First Quarter 2017 Financial Results May 8, 2017 Endo International To Announce Third-Quarter 2017 Financial Results October 8, 2017 Ex-Genentechers' Denali Scores $1B+ Alzheimer's Deal With Takeda January 4, 2018
